A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b.

Mol Ther Oncolytics · 2020 · PMC6940616 · PMID 31909182

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Both results showed a decreasing trend in the percentage of the red blood cell hemolysis caused by human serum complement with increasing CID concentrations.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.